Daiichi Sankyo to pay Merck $170 million for cancer test drug rights
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
HQ Team September 25, 2023: Novo Nordisk and Valo Health, Inc., have signed a $2.7 billion pact to discover and develop novel treatments.
HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.
BioNTech, a German immunotherapy company, announced a strategic pact with OncoC4, a private firm, to develop and commercialise a drug to treat solid tumours.